Correction: Gill et al. Report from the 24th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Richmond, British Columbia, 28–29, October 2022. Curr. Oncol. 2023, 30, 7964–7983

Sharlene Gill(Deventer Ziekenhuis), Karen Mulder, James T. Paul(CancerCare Manitoba), Shahid Ahmed(Emory University), Theresa W. Chan(BC Cancer Agency), Karamjit Gill(BC Cancer Agency), P. Terry Phang(American Society of Colon and Rectal Surgeons), João Paulo Solar Vasconcelos(University of British Columbia), Shazia Mahmood(University of Saskatchewan), Scott Berry, Keith Tankel, Brady Anderson(University of Manitoba), Howard J. Lim(BC Cancer Agency), Mussawar Iqbal(University of Saskatchewan), Ankur Sharma(University of Calgary), Magdalena Recsky(Kelowna General Hospital), Jennifer Nuk(BC Cancer Agency)
Current Oncology
June 3, 2024
10.3390/curroncol31060246
Cited by 1

Related Papers

Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
|JAMA|2017|891
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
|Journal of Clinical Oncology|2009|643